Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Differences in antibody responses of individuals with natural infection and those vaccinated against pandemic H1N1 2009 influenza.

Chan KH, To KK, Hung IF, Zhang AJ, Chan JF, Cheng VC, Tse H, Che XY, Chen H, Yuen KY.

Clin Vaccine Immunol. 2011 May;18(5):867-73. doi: 10.1128/CVI.00555-10. Epub 2011 Mar 16.

2.

Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients.

Ott U, Sauerbrei A, Lange J, Schäfler A, Walther M, Wolf G, Wutzler P, Zell R, Krumbholz A.

Med Microbiol Immunol. 2012 Aug;201(3):297-302. doi: 10.1007/s00430-012-0231-8. Epub 2012 Feb 17.

PMID:
22350187
3.

Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.

Ehrlich HJ, Müller M, Kollaritsch H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, Maritsch F, Aichinger G, Pavlova BG, Barrett PN.

Vaccine. 2012 Jun 22;30(30):4543-51. doi: 10.1016/j.vaccine.2012.03.061. Epub 2012 Apr 1.

PMID:
22475864
4.

Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients.

Chang YT, Guo CY, Tsai MS, Cheng YY, Lin MT, Chen CH, Shen D, Wang JR, Sung JM.

Vaccine. 2012 Jul 13;30(33):5009-18. doi: 10.1016/j.vaccine.2012.05.016. Epub 2012 May 30.

PMID:
22658967
5.

Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers.

Hsu JP, Phoon MC, Koh GC, Chen MI, Lee VJ, Wu Y, Xie ML, Cheong A, Leo YS, Chow VT.

Int J Infect Dis. 2012 Aug;16(8):e621-7. doi: 10.1016/j.ijid.2012.04.010. Epub 2012 Jun 15.

6.

Host immune response to A(H1N1)pdm09 vaccination and infection: a one-year prospective study on six cohorts of subjects.

Liu W, Ma MJ, Tang F, He C, Zhang XA, Jiang LF, Xin DS, Hu CY, Looman C, Cao WC.

Vaccine. 2012 Jul 6;30(32):4785-9. doi: 10.1016/j.vaccine.2012.05.030. Epub 2012 May 24.

PMID:
22633868
7.

Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.

Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.

Pediatrics. 2006 Sep;118(3):e579-85.

PMID:
16950949
8.

Rate of decline of antibody titers to pandemic influenza A (H1N1-2009) by hemagglutination inhibition and virus microneutralization assays in a cohort of seroconverting adults in Singapore.

Hsu JP, Zhao X, Chen MI, Cook AR, Lee V, Lim WY, Tan L, Barr IG, Jiang L, Tan CL, Phoon MC, Cui L, Lin R, Leo YS, Chow VT.

BMC Infect Dis. 2014 Jul 28;14:414. doi: 10.1186/1471-2334-14-414.

9.

Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.

Lagler H, Wenisch JM, Tobudic S, Gualdoni GA, Rödler S, Rasoul-Rockenschaub S, Jaksch P, Redlberger-Fritz M, Popow-Kraupp T, Burgmann H.

Vaccine. 2011 Sep 16;29(40):6888-93. doi: 10.1016/j.vaccine.2011.07.050. Epub 2011 Jul 29.

PMID:
21803100
10.

HI responses induced by seasonal influenza vaccination are associated with clinical protection and with seroprotection against non-homologous strains.

Luytjes W, Enouf V, Schipper M, Gijzen K, Liu WM, van der Lubben M, Meijer A, van der Werf S, Soethout EC.

Vaccine. 2012 Jul 27;30(35):5262-9. doi: 10.1016/j.vaccine.2012.05.060. Epub 2012 Jun 9.

PMID:
22691431
11.

Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v).

Skowronski DM, Janjua NZ, De Serres G, Purych D, Gilca V, Scheifele DW, Dionne M, Sabaiduc S, Gardy JL, Li G, Bastien N, Petric M, Boivin G, Li Y.

J Infect Dis. 2012 Dec 15;206(12):1852-61. doi: 10.1093/infdis/jis500. Epub 2012 Aug 7.

PMID:
22872731
12.

Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, Liu F, Dong L, DeVos JR, Gargiullo PM, Brammer TL, Cox NJ, Tumpey TM, Katz JM.

N Engl J Med. 2009 Nov 12;361(20):1945-52. doi: 10.1056/NEJMoa0906453. Epub 2009 Sep 10.

13.

The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic.

Engelhard D, Zakay-Rones Z, Shapira MY, Resnick I, Averbuch D, Grisariu S, Dray L, Djian E, Strauss-Liviatan N, Grotto I, Wolf DG, Or R.

Vaccine. 2011 Feb 17;29(9):1777-82. doi: 10.1016/j.vaccine.2010.12.113. Epub 2011 Jan 7.

PMID:
21216315
14.

Improved serological response to H1N1 monovalent vaccine associated with viral suppression among HIV-1-infected patients during the 2009 influenza (H1N1) pandemic in the Southern Hemisphere.

Maruszak H, Jeganathan S, Smith DE, Robertson P, Barnes T, Furner V.

HIV Med. 2012 Jul;13(6):352-7. doi: 10.1111/j.1468-1293.2011.00987.x. Epub 2012 Feb 2.

15.

Humoral immune response to influenza A(H1N1)pdm2009 in patients with natural infection and in vaccine recipients in the 2009 pandemic.

Kumagai T, Nakayama T, Okuno Y, Kase T, Nishimura N, Ozaki T, Miyata A, Suzuki E, Okafuji T, Okafuji T, Ochiai H, Nagata N, Tsutsumi H, Okamatsu M, Sakoda Y, Kida H, Ihara T.

Viral Immunol. 2014 Oct;27(8):368-74. doi: 10.1089/vim.2014.0010. Epub 2014 Sep 11.

PMID:
25211638
16.

Comparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults.

Song JY, Cheong HJ, Seo YB, Kim IS, Noh JY, Heo JY, Choi WS, Lee J, Kim WJ.

Clin Vaccine Immunol. 2012 May;19(5):638-41. doi: 10.1128/CVI.00026-12. Epub 2012 Feb 29.

17.

Immunogenicity and safety of a China-made monovalent pandemic (H1N1) 2009 influenza A vaccine in healthcare workers in Guangzhou, China.

Zhan Y, Yang Z, Li L, Ye D, Wu H, Fu R, Zhao S, Wang Y, Zhou R, Chen R.

Jpn J Infect Dis. 2011;64(3):190-4.

18.

Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.

Hakim H, Allison KJ, Van De Velde LA, Li Y, Flynn PM, McCullers JA.

Vaccine. 2012 Jan 20;30(5):879-85. doi: 10.1016/j.vaccine.2011.11.105. Epub 2011 Dec 9.

PMID:
22155630
19.

Neutralizing antibody but not hemagglutination antibody provides accurate evaluation for protective immune response to H5N1 avian influenza virus in vaccinated rabbits.

Zhu H, Ding X, Chen X, Yao P, Xu F, Xie R, Yang Z, Liang W, Zhang Y, Li Y, Shen J, He P, Guo Z, Su B, Sun S, Zhu Z.

Vaccine. 2011 Jul 26;29(33):5421-3. doi: 10.1016/j.vaccine.2011.05.067. Epub 2011 Jun 7.

PMID:
21645575
20.

Seroprevalence of pandemic H1N1 antibody among health care workers in Hong Kong following receipt of monovalent 2009 H1N1 influenza vaccine.

Zhou Y, Ng DM, Seto WH, Ip DK, Kwok HK, Ma ES, Ng S, Lau LL, Peiris JS, Cowling BJ.

PLoS One. 2011;6(11):e27169. doi: 10.1371/journal.pone.0027169. Epub 2011 Nov 10.

Supplemental Content

Support Center